Evommune, Inc. Financing Cash Flow
Evommune, Inc. (EVMN) reported Financing Cash Flow of $117.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Evommune, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $532.00K, a 99.17% decline year-over-year.
- Evommune, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $117.11M.
- Evommune, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $156.85M, a 215.58% increase year-over-year.
- Evommune, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$274.00K.
- Evommune, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $220.76M, a 346.72% increase from fiscal 2024.
- Evommune, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $49.42M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $532.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $117.64M 10-Q · filed 2026-08-06 | $274.49M derived: sum of 3 quarters · filed 2026-08-06 | $274.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $117.11M 10-Q · filed 2026-05-07 | $273.96M derived: sum of 2 quarters · filed 2026-05-07 | $273.69M derived: sum of 3 quarters · filed 2026-05-07 | $338.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $156.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $156.57M derived: sum of 2 quarters · filed 2026-03-05 | $220.91M derived: sum of 3 quarters · filed 2026-08-06 | $220.76M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | $64.07M derived: sum of 2 quarters · filed 2026-08-06 | $63.91M 10-Q · filed 2025-12-11 | $113.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $64.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $64.19M 10-Q · filed 2026-08-06 | $113.89M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$152.00K 10-Q · filed 2026-05-07 | $49.55M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $49.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $49.42M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$282.00K 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |